What’s Guggenheim Updates View on AtaiBeckley Inc (ATAI)?

Guggenheim cited AtaiBeckley’s coagulated fiscal presumption for its renewed bullish presumption connected the stock. According to the firm, AtaiBeckley has capable funds to past it done pivotal readouts successful aboriginal 2029.

In its Q4 2025 study released connected March 6, AtaiBeckley said it closed the twelvemonth with $220.7 cardinal successful cash, currency equivalents, and short-term securities. This accrued from $72.3 cardinal astatine the extremity of 2024. The company’s absorption went connected to accidental that they expected the currency to beryllium capable to money operations into 2029.

AtaiBeckley is underway with respective proceedings programs. These see BPL-003, which enters a Phase 3 proceedings successful Q2 2026. AtaiBeckley is processing BPL-003 arsenic a attraction for terrible depression. According to Guggenheim, the AtaiBeckley absorption sees BPL-003 arsenic presenting a paradigm displacement successful the attraction of terrible depression. The compound’s short-acting illustration is seen arsenic a large differentiator with respect to diligent preference, objective tract preference, and session economics.

AtaiBeckley Inc (NASDAQ:ATAI) is simply a pharmaceutical institution focused connected processing therapies for intelligence wellness conditions. The institution was founded successful 2018 and is based successful Berlin, Germany. AtaiBeckley is 1 of the companies processing psychedelic drugs.

While we admit the imaginable of ATAI arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 8 Must-Buy Small Cap Stocks to Buy and 10 Best Medical AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey connected Google News.